NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Pathobiology


Return to Library

Free Pathobiology Articles


University of Toronto, Banting Institute publishes research in edema therapy



2009 JUL 20 - (NewsRx.com) -- Research findings, 'Pathology and new players in the pathogenesis of brain edema,' are discussed in a new report. According to a study from Toronto, Canada, "Brain edema continues to be a major cause of mortality after diverse types of brain pathologies such as major cerebral infarcts, hemorrhages, trauma, infections and tumors. The classification of edema into vasogenic, cytotoxic, hydrocephalic and osmotic has stood the test of time although it is recognized that in most clinical situations there is a combination of different types of edema during the course of the disease."

"Basic information about the types of edema is provided for better understanding of the expression pattern of some of the newer molecules implicated in the pathogenesis of brain edema. These molecules include the aquaporins, matrix metalloproteinases and growth factors such as vascular endothelial growth factors A and B and the angiopoietins. The potential of these agents in the treatment of edema is discussed," wrote S. Nag and colleagues, University of Toronto, Banting Institute.

The researchers concluded: "Since many molecules are involved in the pathogenesis of brain edema, effective treatment cannot be achieved by a single agent but will require the administration of a 'magic bullet' containing a variety of agents released at different times during the course of edema in order to be successful."

Nag and colleagues published the results of their research in Acta Neuropathologica (Pathology and new players in the pathogenesis of brain edema. Acta Neuropathologica, 2009;118(2):197-217).

For additional information, contact S. Nag, University of Toronto, Dept. of Laboratory Medicine and Pathobiology, Banting Institute, Rm 417, 100 College Street, Toronto, ON M5G1L5, Canada.

The publisher of the journal Acta Neuropathologica can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA.

Keywords: Canada, Toronto, Edema Therapy, Brain Edema, Hemorrhage, Pathology, Therapy, Treatment.

This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.

NewsRx NewsRx NewsRx
-----------------------
PR Login